Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

GLP-1 medications associated with lower risks of Alzheimer's and heart disease, but higher risks of pancreatitis and kidney ...

Realistically, there’s a good chance your patients are using them to get GLP-1 agonists. And sometimes ... care process is the best course of action. We shouldn’t let a patient start with ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...

With promising therapeutic effects comes an increased scrutiny on side effects. GLP-1 receptor agonists mimic the action of the native GLP-1 peptide, enhancing insulin secretion, suppressing glucagon ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Coya Therapeutics expands its pipeline, advancing COYA 303 with a dual immunomodulatory mechanism for inflammatory ... a glucagon-like-peptide-1 receptor agonist (GLP-1 RA) designed for ...

The research found that participants who used the class of drugs which includes Wegovy and Ozempic had a lower risk of 42 ...